Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 5/20 | 0.60 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.45 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.45 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.45 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16832599 | 0.90 | PLA2G2A (0.54) | NQO2PLA2G2AKDM4EPDE3BTACR3 | |
| SCHEMBL16832328 | 0.89 | PLA2G2A (0.64) | NQO2GRM2PLA2G2AKDM4E | |
| SCHEMBL16832378 | 0.88 | GRM2 (0.58) | GRM2KDM4EHPGDSTACR3 | |
| SCHEMBL16832387 | 0.84 | NQO2 (0.60) | NQO2GRM2PLA2G2ASLC2A1SLC2A2 | |
| SCHEMBL16832176 | 0.84 | NQO2 (0.60) | NQO2GRM2PLA2G2AKDM4E | |
| SCHEMBL6605024 | 0.82 | KDM4E (0.65) | NQO2GRM2KDM4E | |
| SCHEMBL16832843 | 0.79 | PLA2G2A (0.69) | NQO2PLA2G2AKDM4E | |
| SCHEMBL18484084 | 0.78 | GRM2 (0.54) | GRM2KDM4EPDE3BHPGDSGRM8 | |
| SCHEMBL16832417 | 0.78 | KDM4E (0.72) | GRM2PLA2G2AKDM4E | |
| SCHEMBL16832968 | 0.78 | NQO2 (0.66) | NQO2GRM2PLA2G2AKDM4ESLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| EP-3083598-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015091428-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | NQO2 338/4885GRM2 817/4885PLA2G2A 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.